<?xml version="1.0" encoding="UTF-8"?>
<p>Fluconazole and fourth generation of azoles (e.g. voriconazole, posaconazole and isavuconazole) remain the most frequently used drugs for treatment of 
 <italic>Candida</italic> infections
 <xref rid="CIT0007" ref-type="bibr">
  <sup>7</sup>
 </xref>. However, azole resistance of 
 <italic>C. albicans</italic> and non-
 <italic>albicans Candida,</italic> such as 
 <italic>C. krusei and C. glabrata,</italic> naturally resistant or low-sensitive to fluconazole, have been reported
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0009" ref-type="bibr">
  <sup>9</sup>
 </xref>. Even if new targets have been successfully explored as well as cell wall formation
 <xref rid="CIT0010" ref-type="bibr">
  <sup>10</sup>
 </xref>, ergosterol synthesis inhibition has been the major objective of new antifungal drugs being ravuconazole and isavucoanzole the most recent clinically available drugs. Most of new antifungal targets presented in the literature exhibited little potential to develop target-based inhibitors being pharmacomodulation of non-toxic azole a good alternative
 <xref rid="CIT0011" ref-type="bibr">
  <sup>11</sup>
 </xref>.
</p>
